AZ PCAstraZeneca PLC 2015 A l G l M ti2015 Annual General ......∂N liti ti l d i di ti (M lti l l...
Transcript of AZ PCAstraZeneca PLC 2015 A l G l M ti2015 Annual General ......∂N liti ti l d i di ti (M lti l l...
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Welcome to our Annual General MeetingWelcome to our Annual General MeetingWelcome to our Annual General Meeting24 April 201524 April 2015p
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Leif JohanssonLeif JohanssonLeif JohanssonChairmanChairman
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Marcus WallenbergMarcus WallenbergMarcus Wallenberg Non Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Geneviève BergerGeneviève BergerGeneviève BergerNon Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Shriti VaderaShriti VaderaShriti VaderaNon Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Graham ChipchaseGraham ChipchaseGraham ChipchaseNon Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
John VarleyJohn VarleyJohn VarleyNon Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Pascal SoriotPascal SoriotPascal SoriotChief Executive OfficerChief Executive Officer
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Marc DunoyerMarc DunoyerMarc DunoyerChief Financial OfficerChief Financial Officer
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Rudy MarkhamRudy MarkhamRudy MarkhamNon Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Bruce BurlingtonBruce BurlingtonBruce BurlingtonNon Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Ann CairnsAnn CairnsAnn CairnsNon Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Jean Philippe CourtoisJean-Philippe CourtoisJean Philippe CourtoisNon Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Leif JohanssonLeif JohanssonLeif JohanssonChairmanChairman
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Nancy Rothwell J h V lNancy Rothwell John VarleyNancy Rothwell John VarleyNon Executive DirectorNon Executive Director Non-Executive DirectorNon-Executive Director
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Cori BargmannCori BargmannCori BargmannProposed Non Executive DirectorProposed Non-Executive Directorp
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Pascal SoriotPascal SoriotPascal SoriotChief Executive OfficerChief Executive Officer
We push the boundaries of science to deliverWe push the boundaries of science to deliverWe push the boundaries of science to deliver plif h i di ilife-changing medicineslife-changing medicineslife changing medicines
2012 2014 20182012-2014 2018+2015 20172012-2014 2018+2015-20172015 2017B ildi t S t i bl d liD li i tBuilding strong Sustainable deliveryDelivering on returnBuilding strong Sustainable delivery Delivering on return
foundations and growthg
t thfoundations and growthto growth gto growth
Three strategic prioritiesThree strategic prioritiesThree strategic prioritiesg p
Achieve Return Be a greatAchieve Return Be a greatAchieve Return Be a great gi tifi t th l t kscientific to growth place to workscientific to growth place to workscientific to growth place to work
l d hileadershipleadershipleadershipp
Achieve scientific leadership: focus on R&D in three mainAchieve scientific leadership: focus on R&D in three mainAchieve scientific leadership: focus on R&D in three main pth d k l tftherapy areas and across key platformstherapy areas and across key platformstherapy areas and across key platforms
Cardio Respirator /Cardio- Respiratory/Cardio Respiratory/ Metabolism inflammationOncology
I f ti &Metabolism inflammationOncology
Infection &gy
Infection & NeuroscienceVaccines NeuroscienceVaccines
Main TAs Opportunity drivenMain TAs Opportunity-drivenpp y
ProteinSmall Protein Biologics Small Immuno therapies Devicesi iBiologics l l Immuno-therapies Devicesengineeringg molecules p engineeringmolecules
Personalised healthcare capabilitiesPersonalised healthcare capabilitiesp
Achieve scientific leadership: 12 approvals in 2014Achieve scientific leadership: 12 approvals in 2014Achieve scientific leadership: 12 approvals in 2014p ppIndustry leading number of US On track to deliver 7 8 potential newIndustry-leading number of US On track to deliver 7-8 potential new y g
NDA/BLA l i 2014p
l l tit b i i i 2015 2016NDA/BLA approvals in 2014 molecular entity submissions in 2015-2016NDA/BLA approvals in 2014 molecular entity submissions in 2015 2016
CAZ AVI (CEPH/BLI)CAZ AVI (CEPH/BLI)serious infectionsserious infections
cediranib (VEGFR) savolitinib (AZD6094 MET)cediranib (VEGFR) savolitinib (AZD6094, MET)ovarian cancer (EU) papillary renal cell carcinomaovarian cancer (EU) papillary renal cell carcinoma
selumetinib (MEK) tremelimumab (CTLA 4)selumetinib (MEK) tremelimumab (CTLA-4)uveal melanoma mesotheliomauveal melanoma mesothelioma
AZD9291 (EGFR) MEDI4736 (PD L1)AZD9291 (EGFR) MEDI4736 (PD-L1)2L NSCLC 3L NSCLC2L NSCLC 3L NSCLC
brodalumab* (IL-17R) roxadustat (HIF PHI)Additional approvals brodalumab (IL-17R) roxadustat (HIF-PHI)Additional approvals psoriasis CKD / ESRD (China)pp psoriasis CKD / ESRD (China)
PT003 (LAMA/LABA) benralizumab (IL 5R)PT003 (LAMA/LABA) benralizumab (IL-5R)COPD severe asthmaCOPD severe asthma
2015 2016D kli G i
2015 2016Duaklir GenuairDuaklir Genuair
* Partner Amgen to manage regulatory submission25
g g g y25
Q1 2015 l l tit † i liQ1 2015 new molecular entity† pipelineQ1 2015 new molecular entity† pipelineQ1 2015 new molecular entity pipeline
Terminations in Q1 2015Terminations in Q1 2015AZD2115 (COPD) in P2 brodalumab (asthma) in P2 MEDI-559 (RSV prophylaxis) in P1AZD2115 (COPD) in P2, brodalumab (asthma) in P2, MEDI 559 (RSV prophylaxis) in P1Divestitures in Q1 2015Divestitures in Q1 2015AZD0914 (infection) in P2AZD0914 (infection) in P2
† Includes significant fixed dose combination projects and parallel indications that are in a separate therapeutic area† Includes significant fixed dose combination projects, and parallel indications that are in a separate therapeutic area (See LCM chart for other parallel indications and oncology combination projects)(See LCM chart for other parallel indications and oncology combination projects)
# Project subject to milestones/royalties# Project subject to milestones/royalties¶ Registrational P2/3 study¶ Registrational P2/3 study∂ N liti ti l d i di ti (M lti l l i P1 t d ti i )∂ Neuromyelitis optica now lead indication (Multiple sclerosis P1 study continuing)
Oncology RIA CVMD Neuroscience Infection26
Oncology RIA CVMD Neuroscience Infection26
Achieve scientific leadership: enhanced collaborationAchieve scientific leadership: enhanced collaborationAchieve scientific leadership: enhanced collaborationpk d ia key drivera key drivera key driver
2727
Return to growth: platforms delivered 15% growth andReturn to growth: platforms delivered 15% growth andReturn to growth: platforms delivered 15% growth and g p g53% f i 201453% of revenue in 201453% of revenue in 201453% of revenue in 2014
$2014 ($m) Growth (%)2014 ($m) Growth (%)($ ) ( )
476 70B ili t /B ili 476 70Brilinta/Brilique 476 70Brilinta/Briliqueq
1 870 139Di b t 1 870 139Diabetes 1,870 139Diabetes ,
5 063 10R i t 5 063 10Respiratory 5,063 10Respiratoryp y
5 827 12Emerging Markets 5 827 12Emerging Markets 5,827 12Emerging Markets
2 227 (3)*Japan 2,227 (3)*Japan 2,227 (3) Japan
Product sales at actual exchange rates. Growth rates at constant exchange rates (CER). *Including impact from mandated price cuts
2828
Great place to workGreat place to workGreat place to workp
I i tIncreases in every categoryIncreases in every categoryin biennial employee surveyin biennial employee surveyp y y
8 %85% 86%85% 86%85% 86%85% 86%Employee Belief in ourEmployee Belief in our p y
engagement strategyengagement strategy(8% increase) (18% increase)(8% increase) (18% increase)
88%88%88%88%ScientificScientific
and patientand patient i t tiorientationorientation
(12% i )(12% increase)( )
2929
Q1 2015: Growth platforms deliverQ1 2015: Growth platforms deliverQ1 2015: Growth platforms deliverQ p
Q1 2015 GrowthQ1 2015 Growth $ %$m %$m %
Total Re en e 6 057 1Total Revenue 6,057 1Total Revenue 6,057 1
Growth Platforms 3 404 13Growth Platforms 3,404 13 ,
Brilinta /Brilique 131 45Brilinta /Brilique 131 45 q
Diabetes 488 47Diabetes 488 47
Respiratory 1 243 7Respiratory 1,243 7
E i M k t 1 533 18Emerging Markets 1 533 18Emerging Markets 1,533 18
J 455 (2)Japan 455 (2)Japan 455 (2)
C EPS $1 08 (3)Core EPS $1 08 (3)Core EPS $1.08 (3)
Total revenue and product sales at actual exchange rates. Growth rates at constant exchange rates (CER)
3030
Oncology our sixth growth platformOncology – our sixth growth platformOncology – our sixth growth platformgy g p
Several potential oncology Oncology trialsSeveral potential oncology Oncology trialsp gyb i i 2015 2016
gyd li t ti lsubmissions 2015-2016 underline potentialsubmissions 2015 2016 underline potential
MEDI4736MEDI4736723L NSCLC 723L NSCLC 72
MET tremelimumabMET tremelimumabpapillary renal th lipapillary renal mesotheliomap p yll i esot e o acell carcinoma 31cell carcinoma 3131
selumetinibAZD9291 selumetinibAZD9291uveal melanomaNSCLC uveal melanomaNSCLC
O l IOncology Immuno-gytrials oncologytrials oncology
trialstrials
3131
Immuno oncologyImmuno-oncologyImmuno-oncologygyT f i t t t Th i f bi tiTransforming treatment The promise of combinations:Transforming treatment The promise of combinations:paradigms for cancer Melanomaparadigms for cancer Melanomapa ad g s o ca ce e a o a
1 Optimising T-cell1. Optimising T-cell f ti dfunction and memoryy
3 Inhibition by2. Antigen 3. Inhibition byi i t
2. Antigen presentation & microenvironmentpresentation &
innate immunityinnate immunity
Postow MA et al. N Engl J Med 2015.gDOI: 10 1056/NEJMoa1414428DOI: 10.1056/NEJMoa1414428
3232
What science can do: AZD9291What science can do: AZD9291What science can do: AZD9291Response rate in T790M positi e cohorts (central test)Response rate in T790M positive cohorts (central test)Response rate in T790M positive cohorts (central test)
505040304030 Best percentage change from baseline in target lesion20 D Best percentage change from baseline in target lesion20 D*D*
100
10DD0 DDD
-10 D
2010 D
DDDD-20 DDDD
D-30 DDD
4030 DD
D D D-40 DD
DDDD DDD D
D
-50DDD D D DD
6050 20 mg
DDDDDDDDD DD-60 40 mg
20 mg DDDDD DDDDDDD-70 40 mg DD
D D D
80-70
80 mgD D DDD D D-80 80 mg
160D
D90 160 mg D
D
100-90 g
240 mgDD
-100 240 mg DD
Deb’s storyDeb s storyy
“Cancer treatment is being personalised and I am a big happy beneficiary of this targeted“Cancer treatment is being personalised and I am a big, happy beneficiary of this targetedg p g, ppy y gth th t I I it j t h t d d lif d t d d lit f lif ”therapy that I am on. I mean it just has extended my life and extended my quality of life.”therapy that I am on. I mean it just has extended my life and extended my quality of life.
Deb is a non smoker with EGFR mutation stage 4 lung cancer who has been on a clinicalDeb is a non-smoker with EGFR mutation stage 4 lung cancer who has been on a clinicalg gtrial with AZD9291 for over a yeartrial with AZD9291 for over a yeary
3333
Total Shareholder ReturnTotal Shareholder Return (1 Jan 2013 to 31 Dec 2014)Total Shareholder Return (1 Jan 2013 to 31 Dec 2014)( )
Rank Share TSRRank Share TSR
1 AstraZeneca PLC 72%1 AstraZeneca PLC 72%
2 f G C %2 Vodafone Group PLC 63%2 Vodafone Group PLC 63%
3 Gl S ithKli PLC 29%3 GlaxoSmithKline PLC 29%3 GlaxoSmithKline PLC 29%
4 U il PLC 28%4 Unilever PLC 28%Unilever PLC 28%
5 British American Tobacco PLC 27%5 British American Tobacco PLC 27%
6 BP PLC 18%6 BP PLC 18%
7 Royal Dutch Shell PLC (B shares) 14%7 Royal Dutch Shell PLC (B-shares) 14%
8 Barclays PLC 13%8 Barclays PLC 13%
9 R l D h Sh ll PLC (A h ) 13%9 Royal Dutch Shell PLC (A-shares) 13%9 Royal Dutch Shell PLC (A shares) 13%
10 Di PLC 11%10 Diageo PLC 11%10 Diageo PLC 11%
S D t tSource: Datastream3434
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
R l tiResolutionsResolutionsResolutions1 To receive the Company’s Accounts and the Reports i) Jean-Philippe Courtois1. To receive the Company s Accounts and the Reports i) Jean Philippe Courtoisy
of the Directors and Auditor for the year ended j) R d M khof the Directors and Auditor for the year ended j) Rudy Markhamy31 D b 2014
j) udy a a31 December 2014 k) Shriti Vadera3 ece be 0 k) Shriti Vadera
l) M W ll b2 To confirm dividends l) Marcus Wallenberg2. To confirm dividends l) Marcus Wallenberg
3 To reappoint KPMG LLP London as Auditor 6 To approve the Annual Report on Remuneration for3. To reappoint KPMG LLP, London as Auditor 6. To approve the Annual Report on Remuneration for pp , pp pthe year ended 31 December 2014the year ended 31 December 2014
4 To authorise the Directors to agree the remunerationy
4. To authorise the Directors to agree the remunerationof the Auditor 7 To authorise limited EU political donationsof the Auditor 7. To authorise limited EU political donations
5 T l t l t th f ll i Di t 8 To authorise the Directors to allot shares5. To elect or re-elect the following as Directors: 8. To authorise the Directors to allot shares5. To elect or re elect the following as Directors:a) Leif Johansson 9 T h i h Di di la) Leif Johansson 9 To authorise the Directors to disapply)b) P l S i
9. To authorise the Directors to disapplyb) Pascal Soriot pre-emption rightsb) Pascal Soriot pre-emption rightsc) Marc Dunoyerc) Marc Dunoyer 10 To a thorise the Compan to p rchase) y 10. To authorise the Company to purchase d) Cori Bargmann
p y pit hd) Cori Bargmann its own shares
) G iè Bits own shares
e) Geneviève Bergere) Geneviève Berger11 To reduce the notice period for general meetingsf) Bruce Burlington 11. To reduce the notice period for general meetingsf) Bruce Burlington) g12 T th d ti f A ti lg) Ann Cairns 12. To approve the adoption of new Articlesg) Ann Cairns 12. To approve the adoption of new Articles
f A i tih) Graham Chipchase of Associationh) Graham Chipchase of Association) p
3636
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
R l tiResolutionsResolutionsResolutions1 To receive the Company’s Accounts and the Reports i) Jean-Philippe Courtois1. To receive the Company s Accounts and the Reports i) Jean Philippe Courtoisy
of the Directors and Auditor for the year ended j) R d M khof the Directors and Auditor for the year ended j) Rudy Markhamy31 D b 2014
j) udy a a31 December 2014 k) Shriti Vadera3 ece be 0 k) Shriti Vadera
l) M W ll b2 To confirm dividends l) Marcus Wallenberg2. To confirm dividends l) Marcus Wallenberg
3 To reappoint KPMG LLP London as Auditor 6 To approve the Annual Report on Remuneration for3. To reappoint KPMG LLP, London as Auditor 6. To approve the Annual Report on Remuneration for pp , pp pthe year ended 31 December 2014the year ended 31 December 2014
4 To authorise the Directors to agree the remunerationy
4. To authorise the Directors to agree the remunerationof the Auditor 7 To authorise limited EU political donationsof the Auditor 7. To authorise limited EU political donations
5 T l t l t th f ll i Di t 8 To authorise the Directors to allot shares5. To elect or re-elect the following as Directors: 8. To authorise the Directors to allot shares5. To elect or re elect the following as Directors:a) Leif Johansson 9 T h i h Di di la) Leif Johansson 9 To authorise the Directors to disapply)b) P l S i
9. To authorise the Directors to disapplyb) Pascal Soriot pre-emption rightsb) Pascal Soriot pre-emption rightsc) Marc Dunoyerc) Marc Dunoyer 10 To a thorise the Compan to p rchase) y 10. To authorise the Company to purchase d) Cori Bargmann
p y pit hd) Cori Bargmann its own shares
) G iè Bits own shares
e) Geneviève Bergere) Geneviève Berger11 To reduce the notice period for general meetingsf) Bruce Burlington 11. To reduce the notice period for general meetingsf) Bruce Burlington) g12 T th d ti f A ti lg) Ann Cairns 12. To approve the adoption of new Articlesg) Ann Cairns 12. To approve the adoption of new Articles
f A i tih) Graham Chipchase of Associationh) Graham Chipchase of Association) p
3838
Please place your completed Polling Card in one of the boxesPlease place your completed Polling Card in one of the boxesPlease place your completed Polling Card in one of the boxesl th tias you leave the meeting roomas you leave the meeting room
We expect to announce the results of the poll later todayWe expect to announce the results of the poll later todayp p y
Th lt f th ll ill l b bli h d th I tThe results of the poll will also be published on the InvestorsThe results of the poll will also be published on the Investorssection of our website: www astrazeneca comsection of our website: www.astrazeneca.com
A Z P CAstraZeneca PLCAstraZeneca PLCAstraZeneca PLCAstraZeneca PLC2015 A l G l M ti2015 Annual General Meeting2015 Annual General Meeting2015 Annual General Meetingg
Th k f tt di d h f j hThank you for attending and have a safe journey homeThank you for attending and have a safe journey home